PARP1 and neoplasm: In a phase I study, when co-administered with TMZ, it inhibited PARP activity and increased DNA damage in patients with advanced solid tumor.Reported increased tumor tissue sensitivity to radiation in vitro and in vivo by inhibiting DNA repair mechanisms in mice bearing U2521 xenografts